ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
ASLN was delisted on the 18th of July, 2024.
7 hedge funds and large institutions have $7.04M invested in ASLAN Pharmaceuticals Limited American Depositary Shares in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 2 closing their positions.
13% less funds holding
Funds holding: 8 → 7 (-1)
34% less capital invested
Capital invested by funds: $10.7M → $7.04M (-$3.66M)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$100K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.03K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HSBC Holdings
London,
United Kingdom
|
-$855K |
| 2 |
FIA
FNY Investment Advisers
New York
|
-$54.7K |
| 3 |
Jane Street
New York
|
-$52K |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$49K |
| 5 |
Millennium Management
New York
|
-$12.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Temasek Holdings
Singapore
| $4.37M | – | – | – |
|
|
2
Baillie Gifford & Co
Edinburgh,
United Kingdom
| $1.32M | -$49K | -331 | -3% |
|
|
PIM
3
Platinum Investment Management
Sydney Australia 2000,
Australia
| $1.27M | +$100K | +676 | +7% |
|
|
FIA
4
FNY Investment Advisers
New York
| $37K | -$54.7K | -370 | -55% |
|
|
5
Millennium Management
New York
| $35K | -$12.9K | -87 | -23% |
|
6
UBS Group
Zurich,
Switzerland
| $9K | -$1.63K | -11 | -13% |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $1K | +$1.03K | +7 | New |
|
|
8
HSBC Holdings
London,
United Kingdom
| – | -$855K | -4,984 | Closed |
|
|
9
Jane Street
New York
| – | -$52K | -299 | Closed |
|
ASLN Hedge Fund Activity: Q2 2019 in Review
7 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) for Q2 2019, worth a combined $7.04M — down 34% from $10.7M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ASLN and 1 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 1 added.
The largest buyer was Platinum Investment Management, adding an estimated $100K. The largest seller was HSBC Holdings, exiting entirely with an estimated $855K sold.
- 7 institutional investors held ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) as of Q2 2019, down from 8 in Q1 2019.
- Funds reported $7.04M of ASLAN Pharmaceuticals Limited American Depositary Shares stock for Q2 2019, down 34% quarter-over-quarter.
- 1 fund opened new ASLAN Pharmaceuticals Limited American Depositary Shares positions in Q2 2019 and 2 closed out, a net change of -1 holder.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares buyer in Q2 2019 was Platinum Investment Management, an estimated $100K added.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares seller in Q2 2019 was HSBC Holdings, an estimated $855K sold.
Based on aggregated 13F filings for Q2 2019.